Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
Summary
As part of a post-approval commitment, the Korean health authority requests a study to characterize safety and effectiveness in patients who are treated with Danicopan as an add-on to ravulizumab or eculizumab in normal clinical practice settings. This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and to evaluate the effectiveness of Danicopan under conditions of routine daily medical practice in Korea.
Official title: Danicopan Regulatory Post-Marketing Study in Korea
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
8
Start Date
2026-03-31
Completion Date
2028-06-27
Last Updated
2026-03-09
Healthy Volunteers
No